Media release Ypsomed and BD expand partnership to address rapidly growing biologics market Burgdorf, 21.01.2026, 1 p.m. – Ypsomed (SIX: YPSN) and BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, are strengthening their collaboration with the development of a 5.5 mL version of the BD Neopak XtraFlow glass prefillable syringe. This innovation is designed to be fully compatible with Ypsomed's YpsoMate 5.5 autoinjector platform, expanding options for pharmaceutical companies and patients who require large‑volume subcutaneous self‑injections. 
Meeting the needs of today and tomorrow's biologics
The new BD Neopak XtraFlow 5.5mL Glass Prefillable Syringe leverages BD advanced technologies, including a shorter, 8-millimeter needle and thinner wall cannulas, to support the delivery of higher volume and viscosity medicines. These enhancements should enable improved injection time1 and optimized flow, addressing common challenges with large-volume biologics and enabling drug developers to move beyond the limitations of standard syringe offerings. "This next generation syringe is a direct response to the growing demand for patient-friendly solutions in the biologics space," said Patrick Jeukenne, Worldwide President of BD Pharmaceutical Systems. "By combining BD's expertise in drug delivery with Ypsomed's leadership in autoinjector platforms, we are helping to simplify self-injection for patients managing complex conditions." Supporting innovation in self-administration
Large‑volume (greater than 1 mL) subcutaneous injections of biologics are increasingly common in areas such as oncology, autoimmune diseases, rare diseases, and metabolic disorders. Ypsomed's YpsoMate 5.5, introduced in 2022, was developed to meet this need, offering an ergonomic design, intuitive two‑step activation, and clear feedback to support patient confidence and ease of use. The new BD Neopak XtraFlow 5.5mL Glass Prefillable Syringe is designed to further enhance the YpsoMate 5.5 platform by maximizing flow efficiency and reducing injection time , critical factors such as dosing volumes and drug viscosities continue to rise. "Ypsomed and BD, in close collaboration with our pharmaceutical partners, are expanding the subcutaneous delivery design space to accommodate high-dose therapies, both volume and viscosity. These partnerships are critical as we jointly drive the future of high-dose biopharmaceutical delivery," said Ulrike Bauer, Chief Business Officer at Ypsomed. A proven partnership for better patient outcomes
BD and Ypsomed have a strong history of collaboration, beginning with the BD Neopak XtraFlow 2.25mL Glass Prefillable Syringe and YpsoMate 2.25 autoinjector. This combination demonstrated improved flow and optimized injection times across a range of drug viscosities, including up to 70cP . The new 5.5 mL version builds on this success, aiming to accelerate and de-risk development of combination products and reduce time-to-market for pharmaceutical companies. Looking ahead
The BD Neopak XtraFlow 5.5mL Glass Prefillable Syringe is currently in development and will undergo comprehensive testing to ensure compatibility with the YpsoMate 5.5 platform. Syringe samples for feasibility studies are expected to be available in mid-2026. Within the same timeline, Ypsomed will expand the YpsoMate 5.5 platform and integrate the BD Neopak XtraFlow 5.5mL Glass Prefillable Syringe. Footnotes
1 When compared to 12.7 mm special thin wall needle. 2 Blaser, T. & Douaire, M. (May 20, 2025). Optimising High Dose Delivery: Syringe–Autoinjector Integration, Injection Time and Performance. ONdrugDelivery, Issue 172, pp. 32–37. Disclaimer
The BD Neopak XtraFlow 5.5mL Glass Prefillable Syringe is a product in development. Some statements are forward-looking and are subject to a variety of risks and uncertainties. BD, the BD Logo, Neopak, and XtraFlow are trademarks of Becton, Dickinson and Company or its affiliates. © 2026 BD. All rights reserved. | 
